Insider Selling: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) CFO Sells 4,139 Shares of Stock
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) CFO Douglas W. Pagan sold 4,139 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total value of $97,597.62. Following the transaction, the chief financial officer now owns 60,000 shares in the company, valued at approximately $1,414,800. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) traded down 2.04% on Friday, hitting $24.05. The stock had a trading volume of 415,479 shares. The company has a 50-day moving average of $22.18 and a 200 day moving average of $18.43. Paratek Pharmaceuticals, Inc. has a 52 week low of $9.80 and a 52 week high of $25.95. The company’s market capitalization is $661.01 million.
Paratek Pharmaceuticals (NASDAQ:PRTK) last released its quarterly earnings data on Thursday, May 4th. The specialty pharmaceutical company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.06. The company had revenue of $0.02 million for the quarter.
WARNING: This news story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/07/16/douglas-w-pagan-sells-4139-shares-of-paratek-pharmaceuticals-inc-nasdaqprtk-stock-updated.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd acquired a new position in shares of Paratek Pharmaceuticals during the fourth quarter worth approximately $158,000. Falcon Point Capital LLC acquired a new position in shares of Paratek Pharmaceuticals during the first quarter worth approximately $200,000. Fox Run Management L.L.C. acquired a new position in shares of Paratek Pharmaceuticals during the second quarter worth approximately $200,000. Russell Investments Group Ltd. acquired a new position in shares of Paratek Pharmaceuticals during the first quarter worth approximately $211,000. Finally, American International Group Inc. increased its position in shares of Paratek Pharmaceuticals by 34.1% in the first quarter. American International Group Inc. now owns 11,111 shares of the specialty pharmaceutical company’s stock worth $214,000 after buying an additional 2,824 shares during the last quarter. 75.43% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have recently commented on PRTK shares. Zacks Investment Research raised Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research report on Thursday, April 20th. HC Wainwright lifted their target price on Paratek Pharmaceuticals from $33.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, April 11th. BTIG Research lifted their target price on Paratek Pharmaceuticals from $47.00 to $56.00 and gave the company a “buy” rating in a research report on Tuesday, April 4th. Guggenheim set a $38.00 target price on Paratek Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, April 4th. Finally, Cantor Fitzgerald set a $33.00 price target on Paratek Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, May 4th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Paratek Pharmaceuticals has a consensus rating of “Buy” and an average price target of $37.00.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Stock Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.